ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements
Medico Remedies appointed V. J. Talati & Co as cost auditor for 12 months. The appointment is an outcome of a board meeting held November 9, 2026.
Medico Remedies Ltd reported revenue from operations of ₹74 Cr (+40.7% YoY) and net profit of ₹2.4 Cr (-7.7% YoY) for Q2 FY27.
Medico Remedies gave advance notice of a 9 November 2026 board meeting to consider unaudited standalone results for the quarter ended September 2026. The trading window is closed from 1 October to 12 November 2026.
Medico Remedies Ltd has filed its quarterly shareholding pattern statement for the period ended September 30, 2026. This is a periodic regulatory compliance filing.
Medico Remedies confirmed to the exchanges that the recent stock price movement is driven by market conditions and no undisclosed information exists.
Medico Remedies Ltd held its 32nd Annual General Meeting on September 22, 2026, transacting ordinary and special business, including director re-appointments and remuneration revisions.
Medico Remedies Ltd has submitted its Annual Report for the financial year 2025-26 and the Notice of its 32nd Annual General Meeting.
Medico Remedies Limited has issued a notice for its 32nd Annual General Meeting scheduled for September 22, 2026. The meeting agenda includes financial statements and director re-appointments.
Medico Remedies Limited announced its 32nd Annual General Meeting scheduled for September 22, 2026. The meeting will seek shareholder approval for financial statements and various director appointments.
Medico Remedies Ltd clarified that recent share price and volume movements are purely market-driven, stating no undisclosed information exists under SEBI regulations.
Medico Remedies Limited has re-appointed Mr. Rishit Mehta and Mr. Haresh Mehta as Executive Directors for a three-year term effective September 18, 2026.
Medico Remedies Ltd reported revenue from operations of ₹69.4 Cr (+81.2% YoY) and net profit of ₹2.5 Cr (+38.9% YoY) for Q1 FY27.
Medico Remedies Limited will hold a board meeting on August 13, 2026, to consider the standalone financial results for the quarter ended June 2026.
Medico Remedies Ltd secured a supply order worth approximately ₹13.38 Crore from PROMESE/CAL, Dominican Republic. This contract involves supplying tablets, capsules, and dry syrups.
Medico Remedies Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ending June 30, 2026.
CRISIL Ratings reaffirmed the credit ratings for Medico Remedies' bank facilities. The total rated facilities amount to ₹42 Crore.
Medico Remedies paid Rs. 1,13,280 in penalties to NSE and BSE for Regulation 6(1) non-compliance. Management confirmed the fine has no material financial impact.
Medico Remedies confirmed it does not meet the SEBI Large Corporate criteria for FY 2025-26. This filing ensures regulatory compliance regarding debt-raising framework applicability.
Medico Remedies Ltd reported revenue from operations of ₹56.8 Cr (+37.5% YoY) and net profit of ₹5.9 Cr (+37.2% YoY) for Q4 FY26.
Medico Remedies reported a total annual income of ₹212.31 Crore for FY2026. The company achieved a net profit of ₹13.11 Crore during this period.
Medico Remedies Ltd received a penalty of ₹0.01 Crore each from NSE and BSE for non-compliance with SEBI Regulation 6(1). The company's waiver applications were rejected by both exchanges. The company has since paid the fines and confirmed compliance as of February 18, 2026.